Medicine & Life Sciences
Neoplasms
100%
Renal Cell Carcinoma
70%
Therapeutics
46%
Non-Small Cell Lung Carcinoma
45%
Diphtheria Toxin
41%
Survival
37%
Immunotoxins
35%
palmitoyl-protein thioesterase
33%
Mutation
32%
Acute Myeloid Leukemia
32%
Proteins
32%
Lung Neoplasms
31%
Drug Therapy
30%
Ricin
28%
Glioblastoma
26%
Nivolumab
26%
Breast Neoplasms
26%
Genes
23%
Brain Neoplasms
21%
Immunotherapy
20%
Safety
20%
Neoplasm Metastasis
19%
Melanoma
19%
Radiotherapy
18%
Clinical Trials
18%
Leukemia
18%
Ceroid lipofuscinosis, neuronal 1, infantile
18%
Progression-Free Survival
18%
anthrax toxin
18%
Pharmaceutical Preparations
17%
Bone Marrow
17%
Cell Line
17%
Prostatic Neoplasms
16%
Growth
16%
Huntingtin Protein
16%
Neuronal Ceroid-Lipofuscinoses
15%
Granulocyte-Macrophage Colony-Stimulating Factor
15%
Enzymes
15%
Glioma
15%
Sunitinib
14%
ErbB Receptors
14%
Stem Cells
14%
T-Lymphocytes
14%
Brain
14%
Colorectal Neoplasms
13%
Monoclonal Antibodies
13%
Ipilimumab
12%
Graft vs Host Disease
12%
In Vitro Techniques
12%
Liver
12%
Recurrence
12%
Antibodies
12%
Transplants
12%
Blood Platelets
12%
Thrombosis
12%
Interleukin-3
12%
alpha-hydroxyglutarate
11%
Protein-Tyrosine Kinases
11%
Heterografts
11%
Sickle Cell Anemia
11%
Adenocarcinoma
11%
DNA
11%
Vascular Endothelial Growth Factor A
11%
Isocitrate Dehydrogenase
11%
Tissue Donors
11%
Apoptosis
10%
Pharmacokinetics
10%
Vitamin B 12
10%
Blood-Brain Barrier
10%
Bone Marrow Transplantation
10%
Kidney Neoplasms
10%
Interleukin-3 Receptors
10%
Population
10%
Multiple Myeloma
10%
Confidence Intervals
10%
Bevacizumab
10%
Fluorouracil
10%
Kidney
9%
Barrett Esophagus
9%
Interleukin-2
9%
Lung
9%
Cisplatin
9%
Lymphoma
9%
Carcinogenesis
9%
Peptides
9%
Everolimus
9%
Small Cell Lung Carcinoma
9%
Thrombocytopenia
9%
Hematologic Neoplasms
9%
Maximum Tolerated Dose
8%
Biomarkers
8%
Pancreatic Neoplasms
8%
Docetaxel
8%
Erlotinib Hydrochloride
8%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8%
Serum
8%
Mechanistic Target of Rapamycin Complex 1
8%
Epithelial Cells
8%
bavituximab
8%
Ligands
8%